161Tb标记放射性药物的研究进展

放射性镧系元素¹⁶¹Tb与广泛使用的放射性核素¹⁷⁷Lu性质相似，且疗效更好，有望成为新型的放射性治疗核素。目前，应用¹⁶¹Tb的研究主要集中于¹⁶¹Tb标记生物分子的体内行为，以及与¹⁷⁷Lu相比，其对恶性肿瘤的疗效。初步的治疗研究表明，在相同的活度下，¹⁶¹Tb在肿瘤治疗方面比¹⁷⁷Lu更有效。本研究对¹⁶¹Tb的特性、制备及其标记放射性药物的研究进展进行综述，为治疗用放射性核素的开发及临床应用提供参考。

Research Progress of 161Tb Labelled Radiopharmaceuticals

The radiolanthanide ¹⁶¹Tb has garnered increasing interest due to its favorable properties for medical application.¹⁶¹Tb showed similar properties to the widely used therapeutic radionuclide ¹⁷⁷Lu, and had better curative effect, which was expected to replace ¹⁷⁷Lu as a new type of therapeutic radionuclide. So far, the studies on the application of ¹⁶¹Tb have mainly focused on the basic in vivo behavior of ¹⁶¹Tb-labeled biomolecules and their effects on malignant tumors compared with ¹⁷⁷Lu. These preliminary therapeutic studies show that ¹⁶¹Tb was more effective than ¹⁷⁷Lu in tumor treatment if the same activity was used. The characteristics, production and research progress of labeled radiopharmaceuticals of ¹⁶¹Tb are reviewed, which can provide reference for the development and clinical application of therapeutic radionuclides.